Premium
Characterization of Prox1 and VEGFR‐3 Expression and Lymphatic Phenotype in Normal Organs of Mice Lacking p50 Subunit of NF‐κB
Author(s) -
FLISTER MICHAEL J.,
VOLK LISA D.,
RAN SOPHIA
Publication year - 2011
Publication title -
microcirculation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.793
H-Index - 83
eISSN - 1549-8719
pISSN - 1073-9688
DOI - 10.1111/j.1549-8719.2010.00057.x
Subject(s) - protein subunit , phenotype , p50 , vegf receptors , lymphatic system , expression (computer science) , biology , microbiology and biotechnology , pathology , anatomy , cancer research , medicine , genetics , gene , computer science , transcription factor , programming language
Please cite this paper as: Flister, Volk and Ran (2011). Characterization of Prox1 and VEGFR‐3 Expression and Lymphatic Phenotype in Normal Organs of Mice Lacking p50 Subunit of NF‐κB. Microcirculation 18 (2), 85–101. Abstract Objective: Inflammation and NF‐κB are highly associated with lymphangiogenesis but the underlying mechanisms remain unclear. We recently established that activated NF‐κB p50 subunit increases expression of the main lymphangiogenic mediators, VEGFR‐3 and its transcriptional activator, Prox1. To elucidate the role of p50 in lymphatic vasculature, we compared LVD and phenotype in p50 KO and WT mice. Methods: Normal tissues from KO and WT mice were stained for LYVE‐1 to calculate LVD. VEGFR‐3 and Prox1 expressions were analyzed by immunofluorescence and qRT‐PCR. Results: Compared with WT, LVD in the liver and lungs of KO mice was reduced by 39% and 13%, respectively. This corresponded to 25–44% decreased VEGFR‐3 and Prox1 expression. In the MFP, LVD was decreased by 18% but VEGFR‐3 and Prox1 expression was 80–140% higher than in WT. Analysis of p65 and p52 NF‐κB subunits and an array of inflammatory mediators showed a significant increase in p50 alternative pathways in the MFP but not in other organs. Conclusions: These findings demonstrate the role of NF‐κB p50 in regulating the expression of VEGFR‐3, Prox1 and LVD in the mammary tissue, liver, and lung.